U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C8H9NO2
Molecular Weight 151.1626
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Acetaminophen

SMILES

CC(=O)NC1=CC=C(O)C=C1

InChI

InChIKey=RZVAJINKPMORJF-UHFFFAOYSA-N
InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)

HIDE SMILES / InChI

Molecular Formula C8H9NO2
Molecular Weight 151.1626
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Acetaminophen, also known as paracetamol, is commonly used for its analgesic and antipyretic effects. Its therapeutic effects are similar to salicylates, but it lacks anti-inflammatory, antiplatelet, and gastric ulcerative effects. Acetaminophen (USAN) or Paracetamol (INN) is a widely used analgesic and antipyretic drug that is used for the relief of fever, headaches, and other minor aches and pains. It is a major ingredient in numerous cold and flu medications and many prescription analgesics. It is extremely safe in standard doses, but because of its wide availability, deliberate or accidental overdoses are not uncommon. Acetaminophen, unlike other common analgesics such as aspirin and ibuprofen, has no anti-inflammatory properties or effects on platelet function, and it is not a member of the class of drugs known as non-steroidal anti-inflammatory drugs or NSAIDs. At therapeutic doses, acetaminophen does not irritate the lining of the stomach nor affect blood coagulation, kidney function, or the fetal ductus arteriosus (as NSAIDs can). Acetaminophen is thought to act primarily in the CNS, increasing the pain threshold by inhibiting both isoforms of cyclooxygenase, COX-1, COX-2, and COX-3 enzymes involved in prostaglandin (PG) synthesis. Unlike NSAIDs, acetaminophen does not inhibit cyclooxygenase in peripheral tissues and, thus, has no peripheral anti-inflammatory affects. Acetaminophen indirectly blocks COX, and that this blockade is ineffective in the presence of peroxides. This might explain why acetaminophen is effective in the central nervous system and in endothelial cells but not in platelets and immune cells, which have high levels of peroxides. Studies also report data suggesting that acetaminophen selectively blocks a variant of the COX enzyme that is different from the known variants COX-1 and COX-2. This enzyme is now referred to as COX-3. Its exact mechanism of action is still poorly understood, but future research may provide further insight into how it works. The antipyretic properties of acetaminophen are likely due to direct effects on the heat-regulating centers of the hypothalamus resulting in peripheral vasodilation, sweating and hence heat dissipation.

Originator

Curator's Comment: was first synthesized in 1877 at Johns Hopkins University by Harmon Northrop Morse

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
TYLENOL

Approved Use

Uses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever

Launch Date

1994
Palliative
TYLENOL

Approved Use

Uses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever

Launch Date

1994
Palliative
TYLENOL

Approved Use

Uses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever

Launch Date

1994
Palliative
TYLENOL

Approved Use

Uses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever

Launch Date

1994
Palliative
TYLENOL

Approved Use

Uses temporarily relieves minor aches and pains due to: minor pain of arthritis, muscular aches, backache, premenstrual abd menstrual cramps, the common cold, headache, toochache; temporary reduce fever

Launch Date

1994
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
28 μg/mL
1000 mg single, intravenous
dose: 1000 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ACETAMINOPHEN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
43 μg × h/mL
1000 mg single, intravenous
dose: 1000 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ACETAMINOPHEN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.4 h
1000 mg single, intravenous
dose: 1000 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ACETAMINOPHEN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
yes [Ki 2300 uM]
yes [Ki 5300 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
no
no
no
no
no
no
yes [Km 1500 uM]
yes [Km 1900 uM]
yes [Km 2300 uM]
yes [Km 3700 uM]
yes [Km 4000 uM]
yes [Km 5500 uM]
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Does TNF-alpha contribute to liver disease physiopathology?].
2000
[Acetaminophen toxicity in children as a "therapeutic misadventure"].
2000 Apr 16
Leukotriene receptor antagonists may prevent NSAID-induced exacerbations in patients with chronic urticaria.
2000 Aug
Acetaminophen produces cataract in DBA2 mice by Ah receptor-independent induction of CYP1A2.
2000 Aug
Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis.
2000 Aug
Hepatocellular response to chemical stress in CD-1 mice: induction of early genes and gamma-glutamylcysteine synthetase.
2000 Aug
Cerebral edema with herniation during acetaminophen-induced fulminant hepatic failure.
2000 Jul
Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates.
2000 Jun 16
Deafness associated with abuse of hydrocodone/acetaminophen.
2000 Jun 27
Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache.
2000 May
N-acetylcysteine in acute hepatic failure (non-paracetamol-induced).
2000 May-Jun
Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank.
2000 Nov
Mechanism of action of acetaminophen: is there a cyclooxygenase 3?
2000 Oct
Peroxisome proliferator-activated receptor alpha-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure.
2000 Oct
Transient neurologic symptoms after epidural analgesia in a five-year-old child.
2000 Oct
Short-term treatment with alcohols causes hepatic steatosis and enhances acetaminophen hepatotoxicity in Cyp2e1(-/-) mice.
2000 Oct 15
Effects of acetaminophen administration to patients in intensive care.
2000 Sep
A prospective study of gastric mucosal ischaemia in paracetamol-induced acute liver failure.
2000 Sep
Transcriptional activation of heme oxygenase-1 and its functional significance in acetaminophen-induced hepatitis and hepatocellular injury in the rat.
2000 Sep
Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations.
2001
Urine drug screens in overdose patients do not contribute to immediate clinical management.
2001 Feb
A novel pH-sensitive membrane from chitosan--TEOS IPN; preparation and its drug permeation characteristics.
2001 Feb
Postoperative analgesia at home after ambulatory hand surgery: a controlled comparison of tramadol, metamizol, and paracetamol.
2001 Feb
Stroke severity determines body temperature in acute stroke.
2001 Feb
Thermodynamic analysis of compact formation; compaction, unloading, and ejection. II. Mechanical energy (work) and thermal energy (heat) determinations of compact unloading and ejection.
2001 Feb 1
Protective effect of stiripentol on acetaminophen-induced hepatotoxicity in rat.
2001 Feb 1
Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media.
2001 Feb 10
Hemolytic anemia after acetaminophen overdose in patient with glucose-6-phosphate dehydrogenase deficiency.
2001 Feb 15
The role of acetaminophen in the management of patients with osteoarthritis.
2001 Feb 19
Idiosyncratic acute hepatitis caused by paracetamol in two patients with melanoma treated with high-dose interferon-alpha.
2001 Feb 20
ABC of diseases of liver, pancreas, and biliary system. Other causes of parenchymal liver disease.
2001 Feb 3
Acetaminophen toxicity induced non-oliguric acute tubular necrosis.
2001 Jan
Simultaneous determination of paracetamol and methocarbamol in tablets by ratio spectra derivative spectrophotometry and LC.
2001 Jan
NSAID impairment of orthodontic tooth movement.
2001 Jan
Separation of cold medicine ingredients by capillary electrophoresis.
2001 Jan
Successful use of propranolol in migraine associated with electroconvulsive therapy.
2001 Jan
Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning.
2001 Jan
The dark side of a 'detoxification' mechanism.
2001 Jan
A comparison of the effect of nitroparacetamol and paracetamol on liver injury.
2001 Jan
One hundred percent online identity check of pharmaceutical products by near-infrared spectroscopy on the packaging line.
2001 Jan
Treatment of acetaminophen ingestion with a superactivated charcoal-cola mixture.
2001 Jan
Effects of rectally administered paracetamol on infants delivered by vacuum extraction.
2001 Jan
High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes.
2001 Jan
Causes of Alzheimer's disease: paracetamol (acetaminophen) today? Amphetamines tomorrow?
2001 Jan
Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg.
2001 Jan 10
Prevention of acetaminophen-induced liver toxicity by 2(R,S)-n-propylthiazolidine-4(R)-carboxylic acid in mice.
2001 Jan 15
Unexpected and pronounced antinociceptive synergy between spinal acetaminophen (paracetamol) and phentolamine.
2001 Jan 26
Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis?
2001 Jan 8
Pediatric acetaminophen poisoning.
2001 Mar
A comparison of ropivacaine and bupivacaine for cervical plexus block.
2001 Mar
Patents

Sample Use Guides

2 caplets every 8 hours with water; don't take more than 6 caplets in 24 hours
Route of Administration: Oral
A time- and concentration-dependent decrease in intracellular GSH occurred in freshly isolated type II pneumocytes and alveolar macrophages exposed to subtoxic (
Substance Class Chemical
Created
by admin
on Wed Apr 02 08:29:06 GMT 2025
Edited
by admin
on Wed Apr 02 08:29:06 GMT 2025
Record UNII
362O9ITL9D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PARACETAMOL
EP   INN   MART.   WHO-DD   WHO-IP  
INN  
Preferred Name English
Acetaminophen
HSDB   INCI   MI   ORANGE BOOK   USP   USP-RS   VANDF  
INCI  
Official Name English
NORCET COMPONENT ACETAMINOPHEN
Common Name English
Acetaminophen [VANDF]
Common Name English
PHENAPHEN
Common Name English
NSC-109028
Code English
DURADYNE DHC COMPONENT ACETAMINOPHEN
Common Name English
TRIAPRIN COMPONENT ACETAMINOPHEN
Common Name English
PERCOCET COMPONENT ACETAMINOPHEN
Common Name English
PARACETAMOLUM [WHO-IP LATIN]
Common Name English
TRIAD COMPONENT ACETAMINOPHEN
Common Name English
ESGIC COMPONENT ACETAMINOPHEN
Common Name English
DHC PLUS COMPONENT ACETAMINOPHEN
Common Name English
PARACETAMOL [WHO-IP]
Common Name English
PERFALGAN
Brand Name English
Acetaminophen [ORANGE BOOK]
Common Name English
LORCET-HD COMPONENT ACETAMINOPHEN
Common Name English
Acetamide, N-(4-hydroxyphenyl)-
Systematic Name English
DAFALGAN
Brand Name English
COMBOGESIC COMPONENT ACETAMINOPHEN
Brand Name English
SEDAPAP COMPONENT ACETAMINOPHEN
Common Name English
OFIRMEV
Brand Name English
MEDIGESIC PLUS COMPONENT ACETAMINOPHEN
Common Name English
DRIXORAL PLUS COMPONENT ACETAMINOPHEN
Common Name English
P-HYDROXY-ACETANILID
Common Name English
PARACETAMOL [MART.]
Common Name English
4?-Hydroxyacetanilide
Systematic Name English
VICODIN COMPONENT ACETAMINOPHEN
Common Name English
Acetaminophen [USP IMPURITY]
Common Name English
EFFERALGAN
Brand Name English
ZYDONE COMPONENT ACETAMINOPHEN
Common Name English
NORCO COMPONENT ACETAMINOPHEN
Common Name English
Acetaminophen [MI]
Common Name English
FEMCET COMPONENT ACETAMINOPHEN
Common Name English
PARACETAMOL [EP MONOGRAPH]
Common Name English
ALLAY COMPONENT ACETAMINOPHEN
Common Name English
BIOCETAMOL
Common Name English
PARACETAMOL [IARC]
Common Name English
APAP
Common Name English
LORTAB COMPONENT ACETAMINOPHEN
Common Name English
NEOPAP
Brand Name English
COMBOGESIC IV COMPONENT ACETAMINOPHEN
Brand Name English
ANEXSIA COMPONENT ACETAMINOPHEN
Common Name English
FIORICET COMPONENT ACETAMINOPHEN
Common Name English
Acetaminophen [JAN]
Common Name English
Acetaminophen [USP-RS]
Common Name English
CODRIX COMPONENT ACETAMINOPHEN
Common Name English
Acetaminophen [USP MONOGRAPH]
Common Name English
PHRENILIN COMPONENT ACETAMINOPHEN
Common Name English
HY-PHEN COMPONENT ACETAMINOPHEN
Common Name English
TYCOLET COMPONENT ACETAMINOPHEN
Common Name English
BUCET COMPONENT ACETAMINOPHEN
Common Name English
TENCON COMPONENT ACETAMINOPHEN
Common Name English
Acetaminophen [HSDB]
Common Name English
ROXICET COMPONENT ACETAMINOPHEN
Common Name English
TREZIX COMPONENT ACETAMINOPHEN
Brand Name English
EXCEDRIN COMPONENT ACETAMINOPHEN
Common Name English
paracetamol [INN]
Common Name English
TYLENOL
Brand Name English
DARVOCET COMPONENT ACETAMINOPHEN
Common Name English
XARTEMIS COMPONENT ACETAMINOPHEN
Brand Name English
NSC-3991
Code English
ULTRACET COMPONENT ACETAMINOPHEN
Common Name English
ANOQUAN COMPONENT ACETAMINOPHEN
Common Name English
N-Acetyl-p-aminophenol
Common Name English
ROXILOX COMPONENT ACETAMINOPHEN
Common Name English
BUTAPAP COMPONENT ACETAMINOPHEN
Common Name English
BANCAP HC COMPONENT ACETAMINOPHEN
Common Name English
Paracetamol [WHO-DD]
Common Name English
DOLIPRANE
Brand Name English
BANCAP COMPONENT ACETAMINOPHEN
Common Name English
TYLOX COMPONENT ACETAMINOPHEN
Common Name English
CO-GESIC COMPONENT ACETAMINOPHEN
Common Name English
VERMIDON
Common Name English
OXYCET COMPONENT ACETAMINOPHEN
Common Name English
ACEPHEN
Brand Name English
WYGESIC COMPONENT ACETAMINOPHEN
Common Name English
INJECTAPAP
Brand Name English
SYNALGOS-DC-A COMPONENT ACETAMINOPHEN
Common Name English
TALACEN COMPONENT ACETAMINOPHEN
Common Name English
DOLENE AP-65 COMPONENT ACETAMINOPHEN
Common Name English
PANADOL
Brand Name English
Classification Tree Code System Code
WHO-ATC N02AJ17
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
CFR 21 CFR 341.40
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
WHO-VATC QN02BE71
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
NCI_THESAURUS C2356
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 7.1
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
WHO-VATC QN02BE01
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
WHO-ATC N02AJ06
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
CFR 21 CFR 862.3030
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
WHO-ATC N02BE71
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
CFR 21 CFR 310.201
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
EPA PESTICIDE CODE 606318
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
WHO-VATC QN02BE51
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
LOINC 75071-1
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
WHO-ATC N02BE51
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
WHO-ATC N02BE01
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
WHO-ATC N02AJ13
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
WHO-ESSENTIAL MEDICINES LIST 2.1
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
LIVERTOX NBK548162
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
WHO-ATC N02AJ01
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
Code System Code Type Description
RS_ITEM_NUM
1003009
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
EVMPD
SUB09611MIG
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
EPA CompTox
DTXSID2020006
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
DAILYMED
362O9ITL9D
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
PUBCHEM
1983
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
DRUG BANK
DB00316
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
WIKIPEDIA
PARACETAMOL
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
CAS
8055-08-1
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
SUPERSEDED
LACTMED
Acetaminophen
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
MERCK INDEX
m1317
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY Merck Index
WHO INTERNATIONAL PHARMACOPEIA
ACETAMINOPHEN
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY Description: A white, crystalline powder; odourless. Solubility: Sparingly soluble in water; freely soluble in ethanol (~750 g/l) TS and acetone R; practically insoluble in ether R. Category: Analgesic; antipyretic. Storage: Paracetamol should be kept in a tightly closed container, protected from light. Definition: Paracetamol contains not less than 98.5% and not more than 101.0% of C8H9NO2, calculated with reference to thedried substance.
INN
626
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
NSC
109028
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
SMS_ID
100000090270
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
ECHA (EC/EINECS)
203-157-5
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
FDA UNII
362O9ITL9D
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
ChEMBL
CHEMBL112
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
DRUG CENTRAL
52
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
RXCUI
161
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY RxNorm
HSDB
3001
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
CHEBI
46195
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
NSC
3991
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
MESH
D000082
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
CAS
103-90-2
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
IUPHAR
5239
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
NCI_THESAURUS
C198
Created by admin on Wed Apr 02 08:29:06 GMT 2025 , Edited by admin on Wed Apr 02 08:29:06 GMT 2025
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
Enzyme responsible for the bulk of NAPQI formation
MAJOR
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
BASIS OF STRENGTH->SUBSTANCE
ASSAY (UV)
USP
Related Record Type Details
PARENT -> METABOLITE
PARENT -> METABOLITE ACTIVE
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE INACTIVE -> PARENT
Major metabolite in infants and young children glucuronide is major metabolite in adults.
MAJOR
URINE
METABOLITE INACTIVE -> PARENT
URINE
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
MAJOR
URINE
METABOLITE ACTIVE -> PARENT
METABOLITE -> PARENT
MINOR
PLASMA
METABOLITE -> PARENT
URINE
METABOLITE ACTIVE -> PARENT
May be substrate for formation of AM-404
MINOR
METABOLITE TOXIC -> PARENT
Metabolite produced hepatic necrosis in man.
AMOUNT EXCRETED
URINE
PARENT -> METABOLITE ACTIVE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (TLC)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC
MAXIMUM TOLERATED DOSE TOXICITY IV, LESS THAN 50 Kg

MAXIMUM TOLERATED DOSE TOXICITY
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
RENAL CLEARANCE PHARMACOKINETIC
MAXIMUM TOLERATED DOSE TOXICITY
MAXIMUM TOLERATED DOSE TOXICITY